ME vs. SKIN, VLTA, OPFI, EMBK, HLLY, SPRY, TYRA, ABVX, CNTA, and IMNM
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Beauty Health (SKIN), Volta (VLTA), OppFi (OPFI), Embark Technology (EMBK), Holley (HLLY), ARS Pharmaceuticals (SPRY), Tyra Biosciences (TYRA), ABIVAX Société Anonyme (ABVX), Centessa Pharmaceuticals (CNTA), and Immunome (IMNM).
Beauty Health (NASDAQ:SKIN) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
93.3% of Beauty Health shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 41.0% of Beauty Health shares are held by company insiders. Comparatively, 27.6% of 23andMe shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Beauty Health presently has a consensus price target of $6.29, indicating a potential upside of 205.13%. 23andMe has a consensus price target of $0.47, indicating a potential upside of 16.31%. Given 23andMe's higher probable upside, analysts clearly believe Beauty Health is more favorable than 23andMe.
Beauty Health has higher revenue and earnings than 23andMe. Beauty Health is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
Beauty Health has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Beauty Health received 28 more outperform votes than 23andMe when rated by MarketBeat users. However, 63.16% of users gave 23andMe an outperform vote while only 48.78% of users gave Beauty Health an outperform vote.
Beauty Health has a net margin of -20.48% compared to Beauty Health's net margin of -303.55%. 23andMe's return on equity of -0.02% beat Beauty Health's return on equity.
In the previous week, 23andMe had 3 more articles in the media than Beauty Health. MarketBeat recorded 3 mentions for 23andMe and 0 mentions for Beauty Health. 23andMe's average media sentiment score of 0.00 equaled Beauty Health'saverage media sentiment score.
Summary
Beauty Health beats 23andMe on 11 of the 17 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
